{"entity":{"type":"insider","cik":"0001385115","url":"/insider/0001385115","json_url":"/insider/0001385115.json","name":"Maimon Yossi","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":14,"n_filings":9,"first":"2008-02-26","last":"2015-12-15","span_basis":"filed_date"},"name_variants":[{"name":"Maimon Yossi","source":"filing","n_filings":8,"first_seen":"2009-03-13","last_seen":"2015-12-15"},{"name":"Yossi Maimon","source":"filing","n_filings":1,"first_seen":"2008-02-26","last_seen":"2008-02-26"}],"transactions":[{"id":8673728,"accession":"0001144204-15-070834","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-15-070834","line_url":"/filing/0001144204-15-070834#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (Vice President & CFO)","role_mark":"O","role_mark_label":"Officer (Vice President & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.78,"price_display":"0.78","price_state":"stated","total_value":7800.0,"total_display":"7,800.00","total_whole":"7,800","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-14","filed_date":"2015-12-15","scope":"insider"},{"id":2947765,"accession":"0001144204-12-026352","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-12-026352","line_url":"/filing/0001144204-12-026352#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125964.0,"shares_display":"125,964","price_per_share":7.13,"price_display":"7.13","price_state":"stated","total_value":898123.32,"total_display":"898,123.32","total_whole":"898,123","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-02","filed_date":"2012-05-04","scope":"insider"},{"id":7630688,"accession":"0001209191-10-049835","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-10-049835","line_url":"/filing/0001209191-10-049835#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":70000.0,"shares_display":"70,000","price_per_share":9.67,"price_display":"9.67","price_state":"stated","total_value":676900.0,"total_display":"676,900.00","total_whole":"676,900","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-10-07","filed_date":"2010-10-08","scope":"insider"},{"id":7488159,"accession":"0001209191-10-045451","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-10-045451","line_url":"/filing/0001209191-10-045451#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31500.0,"shares_display":"31,500","price_per_share":8.16,"price_display":"8.16","price_state":"stated","total_value":257040.0,"total_display":"257,040.00","total_whole":"257,040","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-09-07","filed_date":"2010-09-08","scope":"insider"},{"id":7488153,"accession":"0001209191-10-045451","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-045451","line_url":"/filing/0001209191-10-045451#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38500.0,"shares_display":"38,500","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":308000.0,"total_display":"308,000.00","total_whole":"308,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-09-03","filed_date":"2010-09-08","scope":"insider"},{"id":6018513,"accession":"0001209191-09-049178","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-09-049178","line_url":"/filing/0001209191-09-049178#line-4","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40300.0,"shares_display":"40,300","price_per_share":9.35,"price_display":"9.35","price_state":"stated","total_value":376805.0,"total_display":"376,805.00","total_whole":"376,805","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-16","filed_date":"2009-10-19","scope":"insider"},{"id":6018504,"accession":"0001209191-09-049178","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-049178","line_url":"/filing/0001209191-09-049178#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":109700.0,"shares_display":"109,700","price_per_share":9.5,"price_display":"9.50","price_state":"stated","total_value":1042150.0,"total_display":"1,042,150.00","total_whole":"1,042,150","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-15","filed_date":"2009-10-19","scope":"insider"},{"id":5769120,"accession":"0001209191-09-036035","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-09-036035","line_url":"/filing/0001209191-09-036035#line-4","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":5.01,"price_display":"5.01","price_state":"stated","total_value":50100.0,"total_display":"50,100.00","total_whole":"50,100","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-07-07","filed_date":"2009-07-08","scope":"insider"},{"id":5769117,"accession":"0001209191-09-036035","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-036035","line_url":"/filing/0001209191-09-036035#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":5.13,"price_display":"5.13","price_state":"stated","total_value":205200.0,"total_display":"205,200.00","total_whole":"205,200","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-07-06","filed_date":"2009-07-08","scope":"insider"},{"id":5624444,"accession":"0001209191-09-027624","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-027624","line_url":"/filing/0001209191-09-027624#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":120000.0,"total_display":"120,000.00","total_whole":"120,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-18","filed_date":"2009-05-19","scope":"insider"},{"id":6037846,"accession":"0001209191-09-016290","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-09-016290","line_url":"/filing/0001209191-09-016290#line-5","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":2.23,"price_display":"2.23","price_state":"stated","total_value":16725.0,"total_display":"16,725.00","total_whole":"16,725","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-03-13","filed_date":"2009-03-13","scope":"insider"},{"id":6037837,"accession":"0001209191-09-016290","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-016290","line_url":"/filing/0001209191-09-016290#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32241.0,"shares_display":"32,241","price_per_share":2.22,"price_display":"2.22","price_state":"stated","total_value":71575.02,"total_display":"71,575.02","total_whole":"71,575","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-03-12","filed_date":"2009-03-13","scope":"insider"},{"id":6037834,"accession":"0001209191-09-016290","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-016290","line_url":"/filing/0001209191-09-016290#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Maimon Yossi","owner_display_name":"Maimon Yossi","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8849.0,"shares_display":"8,849","price_per_share":2.3,"price_display":"2.30","price_state":"stated","total_value":20352.7,"total_display":"20,352.70","total_whole":"20,353","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-03-11","filed_date":"2009-03-13","scope":"insider"},{"id":3579457,"accession":"0001385115-08-000001","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001385115-08-000001","line_url":"/filing/0001385115-08-000001#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385115","owner_name":"Yossi Maimon","owner_display_name":"Yossi Maimon","owner_url":"/insider/0001385115","role":"Officer (VP, Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33300.0,"shares_display":"33,300","price_per_share":3.176,"price_display":"3.18","price_state":"stated","total_value":105760.8,"total_display":"105,760.80","total_whole":"105,761","shares_owned_after":26700.0,"shares_owned_after_display":"26,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-02-25","filed_date":"2008-02-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":14,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":13,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":14},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001006281","name":"Protalix BioTherapeutics, Inc.","url":"/issuer/0001006281","role":"Officer (Vice President & CFO)","n_filings":9,"first_seen":"2008-02-26","last_seen":"2015-12-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001385115","retrieved_at":"2026-08-22T21:05:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}